129 related articles for article (PubMed ID: 36271359)
1. Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
Yi GZ; Zhu TC; Que TS; Li ZY; Huang GL
BMC Neurol; 2022 Oct; 22(1):390. PubMed ID: 36271359
[TBL] [Abstract][Full Text] [Related]
2. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden.
Zheng S; Wang F; Huang J; Zhou Y; Yang Q; Qian G; Zhou C; Min D; Song L; Shen Z
Front Endocrinol (Lausanne); 2021; 12():625226. PubMed ID: 34220700
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
Pfaff E; Kessler T; Balasubramanian GP; Berberich A; Schrimpf D; Wick A; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Capper D; Schenkel I; Eisenmenger A; Dettmer S; Brors B; Platten M; Pfister SM; von Deimling A; Jones DTW; Wick W; Sahm F
Neuro Oncol; 2018 May; 20(6):826-837. PubMed ID: 29165638
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of a
Zureick AH; McFadden KA; Mody R; Koschmann C
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31154346
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
7. Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome.
Pavelka Z; Zitterbart K; Nosková H; Bajčiová V; Slabý O; Štěrba J
Klin Onkol; 2019; 32(1):70-74. PubMed ID: 30764633
[TBL] [Abstract][Full Text] [Related]
8. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
9. Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
Natsume A; Aoki K; Ohka F; Maeda S; Hirano M; Adilijiang A; Motomura K; Sumi M; Nishikawa R; Narita Y; Muragaki Y; Maruyama T; Ito T; Beppu T; Nakamura H; Kayama T; Sato S; Nagane M; Mishima K; Nakasu Y; Kurisu K; Yamasaki F; Sugiyama K; Onishi T; Iwadate Y; Terasaki M; Kobayashi H; Matsumura A; Ishikawa E; Sasaki H; Mukasa A; Matsuo T; Hirano H; Kumabe T; Shinoura N; Hashimoto N; Aoki T; Asai A; Abe T; Yoshino A; Arakawa Y; Asano K; Yoshimoto K; Shibui S; Okuno Y; Wakabayashi T;
J Neurooncol; 2020 May; 148(1):17-27. PubMed ID: 32367437
[TBL] [Abstract][Full Text] [Related]
10. Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.
Sa JK; Choi SW; Zhao J; Lee Y; Zhang J; Kong DS; Choi JW; Seol HJ; Lee JI; Iavarone A; Rabadan R; Nam DH
Int J Cancer; 2019 Jun; 144(12):3023-3030. PubMed ID: 30536544
[TBL] [Abstract][Full Text] [Related]
11. Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases.
Wang D; Niu X; Wang Z; Song CL; Huang Z; Chen KN; Duan J; Bai H; Xu J; Zhao J; Wang Y; Zhuo M; Xie XS; Kang X; Tian Y; Cai L; Han JF; An T; Sun Y; Gao S; Zhao J; Ying J; Wang L; He J; Wang J
Cancer Res; 2019 Jan; 79(1):7-20. PubMed ID: 30389703
[TBL] [Abstract][Full Text] [Related]
12. Experimental Study of Somatic Variants of Osteosarcoma by Whole-Exome Sequencing.
Hou J; Liu G; Zhang P; Wang B; Yan Q; Wu P; Wang C; Yao W
Med Sci Monit; 2020 Mar; 26():e920826. PubMed ID: 32193367
[TBL] [Abstract][Full Text] [Related]
13. Extensive Therapies for Extraneural Metastases from Glioblastoma, as Confirmed with the OncoScan Assay.
Xu M; Wang Y; Xu J; Yao Y; Yu WX; Zhong P
World Neurosurg; 2016 Jun; 90():698.e7-698.e11. PubMed ID: 26852708
[TBL] [Abstract][Full Text] [Related]
14. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
15. A case study of a long-term glioblastoma survivor with unmethylated
Jue TR; Olafson LR; Siddell AH; Rapkins RW; Ng B; Yin JXM; Lu VM; Chung SA; Whittaker SP; Davies M; Fairhall JM; Hovey EJ; McDonald KL
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160353
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
17. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
18. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract][Full Text] [Related]
19. [Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing].
Gao DL; Dong RF; Liu WF; Gong LH; Xu HR; Niu XH; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):370-375. PubMed ID: 36973198
[No Abstract] [Full Text] [Related]
20. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]